Fundraising Fox
🦊/People
Sign in

Ann DeWitt

Investor

General Partner at The Engine Ventures · Board director at Dropletbiosci · Board director at Kano Therapeutics · Board director at Quaise

Cambridge, Massachusetts, United States

Find your path to Ann

1,141 people in our graph share verified history with Ann — schools, employers, funds. One of them is your warm intro.

Wesley ChanunlockedAnn: together at Massachusetts Institute of Technology (1996–2001)
×3Ann: together at University of Illinois Urbana-Champaign
×3Ann: together at Massachusetts Institute of Technology
×3Ann: together at Harvard Business School

About

Ann DeWitt is a General Partner at Engine Ventures with experience as an executive, investor, and advisor. She sits on numerous life science company boards, previously held business development and strategic venture roles at Sanofi and worked at Flagship Pioneering, began her career in R&D at 3M, and holds a PhD in Chemical Engineering from MIT and an MBA from Harvard Business School.

Contact· self-published, not guessed

Invests in

BiotechClimate TechDeep TechEnergyHardwareHealthtech

Board director at Dropletbiosci

Intro paths

→

In turn, Ann can intro founders to Dropletbiosci's investors below.

Dropletbiosci's investors · 2

Safar PartnersCambridgeThe Engine VenturesCambridge

Board director at Kano Therapeutics

Intro paths

→

In turn, Ann can intro founders to Kano Therapeutics's investors below.

Kano Therapeutics's investors · 6

Fifty YearsSan Francisco · $250K – $2M checks · since 2024Launchpad Venture GroupBoston · $8M – $10M checks · since 2024MetaplanetTallinn · $500K – $10M checks · since 2024The Engine VenturesCambridge · since 2024Vsquared VenturesMünchen · since 2024ZAKA VCSan Francisco · since 2024

Board director at Quaise

Intro paths

→

In turn, Ann can intro founders to Quaise's investors below.

Quaise's investors · 12

8090 IndustriesNew YorkCollaborative FundNew York · $500K – $1M checksFine Structures VenturesCambridgeHelium-3 VenturesNew YorkIdemitsu Kosansince 2026JERATokyo · since 2026Prelude VenturesSan Francisco · $100K – $5M checks · since 2026Safar PartnersCambridge · since 2022Starlight VenturesMiami · $100K – $3M checksTechEnergy VenturesBuenos AiresThe Engine VenturesCambridgeXplorer CapitalMenlo Park

Co-founders at Quaise

MHMatt Houde
Matt HoudeFounder
CACarlos Araque
Carlos AraqueFounder

Experience

  1. Engine VenturesGeneral Partnercurrent2023 — presentCambridge, Massachusetts, United States
  2. NucleateBoard Membercurrent2023 — presentBoston, MA
  3. Harvard Blavatnik Fellowship in Life Science EntrepreneurshipCouncil Membercurrent2020 — presentBoston, Massachusetts, United States
  4. The EngineGeneral Partner2019 — 2023Cambridge, MA
  5. The EngineCOO2018 — 2019Cambridge, MA
  6. Springboard EnterprisesLife Sciences Council member2010 — 2023
  7. WEST - Women in the Enterprise of Science and TechnologyBoard Director & Advisory Board co-chair2016 — 2019Cambridge, MA
  8. SanofiSenior Director, Business Development & Licensing Transactions2016 — 2018Cambridge, MA
  9. SanofiSenior Director of Investments2013 — 2016Cambridge, MA
  10. Permeon BiologicsSenior Director, Corporate Development2011 — 2013One Kendall Square
  11. Flagship VenturesSenior Associate2009 — 2011Cambridge, MA
  12. University of MinnesotaVenture Center Advisor2006 — 2007
  13. 3M CompanyResearch Specialist2001 — 2006St. Paul, MN

Skills & more

Biotechnology17Lifesciences5Business Planning4Venture Capital19Entrepreneurship13Start-ups13Leadership11Strategic Planning4Management3Pharmaceutical Industry6Strategy17R&D3
+4 moreBusiness StrategyBiopharmaceuticalsLife SciencesBusiness Development
  • Nucleate Leadership Council Member — Nucleate

From Ann's professional profile.

Investments

Board seats

BexorgCellino BioDropletbiosciKano TherapeuticsMatrisome BioPredicta BiosciencesSource BioVaxess Technologies

Per the firm's website.

Colleagues at The Engine Ventures

Alaina Hartnett
Associate at The Engine Ventures
Bettina Metais
Vice President of Investor Relations & Operations at The Engine Ventures
Colleen Calhoun
Investor at BURNT ISLAND VENTURES
Dan Resnicow
Operating Partner at The Engine Ventures
Darby Dunn
Executive in Residence at The Engine Ventures
David Bradwell
Operating Partner at The Engine Ventures
Deepa Rao
Associate at The Engine Ventures
Ericka Tamayo-Guevara
Analyst at The Engine Ventures

Network7

Vinod KhoslaScout
Founder of Khosla Ventures
Chris GibsonScout
Portfolio Director, Private Equity at Bridges Fund Management Ltd.
Katie RaeScout
CEO and Managing Partner at The Engine Ventures
Rayyan IslamScout
Co-Founder and General Partner at 8090 Industries
Reed SturtevantScout
General Partner at The Engine Ventures
David Hendrickson
Founding Partner at Helium-3 Ventures
Jim Matheson
Investor at G20 Ventures

Investors connected to Ann in public investor directories — a warm-intro map.

Frequently asked questions

Who is Ann DeWitt?
Ann DeWitt is a General Partner at Engine Ventures with experience as an executive, investor, and advisor. She sits on numerous life science company boards, previously held business development and strategic venture roles at Sanofi and worked at Flagship Pioneering, began her career in R&D at 3M, and holds a PhD in Chemical Engineering from MIT and an MBA from Harvard Business School.
Where does Ann DeWitt work?
Ann DeWitt is General Partner at The Engine Ventures and Board director at Dropletbiosci and Board director at Kano Therapeutics and Board director at Quaise.
What does Ann DeWitt invest in?
Ann DeWitt invests in Biotech, Climate Tech, Deep Tech, Energy, Hardware, Healthtech.
What boards does Ann DeWitt sit on?
Ann DeWitt holds tracked board seats at Bexorg, Cellino Bio, Dropletbiosci, Kano Therapeutics, Matrisome Bio, Predicta Biosciences, Source Bio, Vaxess Technologies.
Where did Ann DeWitt go to school?
Ann DeWitt studied at Harvard Business School (MBA); Massachusetts Institute of Technology (Ph.D., Chemical Engineering); University of Illinois Urbana-Champaign (B.S., Chemical Engineering).

Same school

Shared employers